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A B S T R A C T
Hepatitis C virus (HCV) infection facilitates the development of hepatocellular carcinoma (HCC). Acti-
vation of Ras/Raf/MEK/ERK pathway is found in more than 30% human cancers. Here, we revealed a novel
mechanism underlying the regulation of hepatoma cell proliferation mediated by HCV. On one hand, hepa-
toma cell proliferation is facilitated by HCV infection through a positive feedback regulatory cycle. HCV
promotes hepatoma cell proliferation by activating the Ras/Raf/MEK/ERK pathway, which in turn facili-
tates HCV replication to further enhance hepatoma cell proliferation. On the other hand, hepatoma cell
proliferation is attenuated by the bromodomain containing 7 (BRD7), a tumor suppressor, through a neg-
ative feedback regulatory mechanism. After activation, the Ras/Raf/MEK/ERK pathway stimulates BRD7
production, which in turn represses the Ras/Raf/MEK/ERK pathway, leading to the attenuation of hepa-
toma cell proliferation. However, HCV persistent infection attenuates BRD7 gene expression and facilitates
the protein degradation to release the Ras/Raf/MEK/ERK signaling, which results in the facilitation of hepa-
toma cell proliferation. Therefore, we proposed that the balance between BRD7 function and Ras/Raf/
MEK/ERK activity is important for determining the outcomes of HCV infection and HCC development.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Hepatitis C virus (HCV) infection can cause hepatocellular car-
cinoma (HCC), a liver cancer with a global health burden [1–5]. HCV
infects more than 170 million people worldwide, and most infec-
tions are diﬃcult to be eradicated [6–8]. HCV is an enveloped virus
with a single positive-stranded RNA genome, which encodes a large
polyprotein that is post-translationally processed into 10 individ-
ual proteins by cellular and viral proteases [9,10]. Among the viral
proteins, Core, E2, NS3, and NS5A were reported to be involved in
HCV-induced hepatocarcinogenesis [11].
It is reported that activation of Ras/Raf/MEK/ERK pathway has
occurred in more than 30% human cancers [12]. This pathway has
a great diversity of biological functions, including cell prolifera-
tion, differentiation, apoptosis, cell cycle regulation, and drug
resistance [13–15]. Dysregulation of the pathway leads to tumori-
genesis, and therefore, its inhibitors would be potential candidates
for cancer therapy [16,17]. There are three important kinases in
the pathway, Raf, MEK, and ERK. Signals are transmitted by means
of the sequential phosphorylation of the kinases. Once an extra-
cellular stimulus occurs, the Grb2-SOS complex was brought in
the proximity of Ras and induces Ras into an active GTP-bound
state. Raf is recruited by activated Ras to the plasma membrane,
then phosphorylated by itself or other kinases. Activated Raf phos-
phorylates MEK, which in turn activates the downstream
effector ERK. Activation of ERK is able to induce the expression of
many transcription factors involved in a wide range of cellular
functions.
Bromodomain containing 7 (BRD7) is amember of bromodomain-
containing proteins, which are involved in chromatin remodeling,
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cell cycle regulation, and transcription regulation [18,19]. BRD7 has
been found as a subunit of the polybromo-associated BRG1-
associated factor (PBAF) complex [20], and plays a tumor-suppressive
role in nasopharyngeal carcinoma (NPC) [21], epithelial ovarian
carcinoma (EOC) [22], osteosarcoma (OS) [23,24], and colorectal
cancer (CRC) [25–27]. Moreover, BRD7 is required for gene tran-
scriptions regulated by well-known tumor suppressors, p53 and
BRCA1 [26,27].
We previously studied the mechanism underlying HCV regu-
lates HCC development and demonstrated that activation of Ras/
Raf/MEK/ERK pathway plays an important role in the regulation of
HCC [28–30]. In this study, we further revealed a novel mechanism
bywhichHCV regulates hepatoma cell proliferation.Our results dem-
onstrated thatHCVstimulates theRas/Raf/MEK/ERKpathway through
a positive feedback regulatory mechanism and attenuates the pro-
duction of BRD7 by a negative feedback mechanism, which lead to
the facilitation of human hepatoma cell proliferation and HCC de-
velopment. Therefore, we proposed that the balance between the
activity of Ras/Raf/MEK/ERK and the function of BRD7 is important
fordetermining theoutcomesofHCV infectionandHCCdevelopment.
Materials and methods
Cells and viruses
Human hepatoma cell line Huh7.5.1 was kindly provided by Dr. Francis Chisari
and cultured in Dulbecco’s modiﬁed Eagle’s medium (Gibco) supplemented with
10% fetal calf serum (Gibco), 100 U/ml penicillin, and 100 μg/ml streptomycin sulfate.
The cells were maintained at 37 °C in a 5% CO2 incubator.
HCV genotype 2a strain JFH-1 was kindly provided by Dr. Takaji Wakita. Cells
were infected with JFH-1 at a multiplicity of infection (MOI) of 0.1–1 for 7 days. Stock
virus was made by collecting and ﬁltering the supernatant of infected cell cultures
[31,32], and the viral titer was measured with a commercial kit (HCV RNA qPCR di-
agnostic kit, KHB Company). Aliquots were stored at −80 °C until use.
Plasmids, small interfering RNAs, antibodies, and inhibitors
Plasmid pcDNA3.1-Ras (V12) encoding an activated Harvey-Ras (Ha-Ras) [33]
was constructed previously by our group [34]. The plasmid pFlag-CMV-BRD7 was
constructed by inserting the cDNA clone of BRD7 kindly provided by Dr. Jiahua Han
into vector p3XFLAG-CMV-14. The primers used in plasmid construction are listed
in Table 1.
The shRNA of BRD7 (shBRD7) and control shRNA (shCtrl) were purchased from
GenePharma. The target sequence of shBRD7 is 5′-GCGAATTTGAAAGAAGAAAAC-3′.
The antibody to HCV Core protein (ab2740) was purchased from Abcam. The an-
tibody to Flag (F3165) was purchased from Sigma. The antibody to ERK (sc-153) was
purchased from Santa Cruz. The antibody to p-ERK (#4370) was purchased from Cell
Signaling. The antibody to BRD7 (51009-2-AP) was purchased from Proteintech. The
antibody to GAPDH was purchased from CWBio.
U0126, an inhibitor of Ras/Raf/MEK/ERK pathway, was purchased from Tocris
Bioscience, and dissolved in dimethyl sulfoxide (Sigma).
RNA extraction and real-time PCR
Total RNA was extracted from cells with TRIzol reagent (Invitrogen) according
to the manufacturer’s instructions. The RNA extract was treated with DNase I
(Promega) at 37 °C for 30 min. 1 mg of the RNA extract was used as a template for
reverse transcription by murine leukemia virus reverse transcriptase (MLV RT)
(Promega) with random primers at 37 °C for 60 min.
Real-time PCR was performed in a LightCycler 480 thermal cycler (Roche) under
the following conditions: heat activation of the polymerase at 95 °C for 5 min, fol-
lowed by 40 cycles of 95 °C for 15 s, 55 °C for 15 s, and 72 °C for 20 s. The ﬂuorescence
was measured at the 72 °C step. A ﬁnal melting curve step from 50 °C to 95 °C was
performed to examine the quality of the detection primers. The primers used in real-
time detection are listed in Table 1.
Cell transfection
Cells were seeded at a density of 8 × 104 cells per well in 24-well plates, and
grew to approximately 80% conﬂuence prior to transfection. Plasmids were trans-
fected into cells with Lipofectamine 2000 reagent (Invitrogen). Assays were performed
in triplicate, and results are expressed as mean luciferase activities ± standard de-
viations (SD).
Cell viability and proliferation assays
The cell viability was measured with Cell Counting Kit 8 (CCK8). In brief, cells
were seeded in a 96-well plate and processed according to the experimental design.
On the day of detection, 10 μl of CCK8 reagent was added into the cell supernatant,
and the OD450nm value was detected 1 h later. There are 6 replicate wells for each
sample, and the result was expressed as the mean value ± standard deviations (SD).
Cells were seeded in a 6-well plate and processed according to the experimen-
tal design. On the day of detection, cells were trypsinized in situ and dispersed
thoroughly, then the plate was transferred to an inverted optical microscope
(Olympus). Each plate well was observed and photographed with a 4× objective lens.
The cell number on the photo was counted by the software named “ImageJ”. Three
independent visual ﬁelds were counted for each plate well, and the result was ob-
tained as the mean cell number. Each sample well was normalized with the control
well, and the ﬁnal result was expressed as the fold of the control.
Cytoplasm and nucleus extractions
This experiment was performed with a commercial kit (NE-PER, Thermo). Brieﬂy,
cells were collected and incubated with reagent CER I and CER II for 1 min on ice.
Then the samples were centrifuged at 16,000 g for 5 min, and the supernatant
(cytoplasmic extract) was collected in a clean pre-chilled tube for further use. The
insoluble fraction of each sample was suspended with ice-cold reagent NER. Each
sample was vortexed for 15 s every 10 min, for a total of 40 min. After centrifuga-
tion at 16,000 g for 10min, the supernatant (nuclear extract) was collected in a clean
pre-chilled tube for further use.
Statistical analyses
All experiments were reproducible and repeated at least three times with similar
results. Parallel samples were analyzed for normal distribution using Kolmogorov–
Smirnov tests. Abnormal values were eliminated using a follow-up Grubbs test.
Levene’s test for equality of variances was performed, which provided information
for Student’s t-tests to distinguish the equality of means. Means were illustrated using
histograms with error bars representing the SD; a p value of <0.05 was considered
statistically signiﬁcant.
Results
HCV facilitates the viability and proliferation of human hepatoma
cells through activating the Ras/Raf/MEK/ERK pathway
Initially, the effects of HCV infection on the viability and prolif-
eration of human hepatoma cells were evaluated in Huh7.5.1 cells
infected with HCV. The cell viability was monitored by using CCK8
assay kits, in which OD450nm value representing cell viability. The
Table 1
Primer used in this study.
Gene Sequences
BRD7-forward
(PC)*
5′-TTTGCGGCCGCGCCACCATGGGCAAGAAGCACAAGA-3′
BRD7-reverse
(PC)*
5′-TTTGGTACCGAACTTCCACCAGGTCCACACTC-3′
BRD7-forward
(RT)**
5′-TCTTGGGTCCCTCATACA-3′
BRD7-reverse
(RT)**
5′-ACTCAGCAACATCCGTCT-3′
Cyclin D1-forward
(RT)**
5′-GAACACGGCTCACGCTTAC-3′
Cyclin D1-reverse
(RT)**
5′-CCAGACCCTCAGACTTGC-3′
c-Fos-forward
(RT)**
5′-CAGGGCTGGCGTTGTGA-3′
c-Fos-reverse
(RT)**
5′-CGGTTGCGGCATTTGG-3′
c-Myc-forward
(RT)**
5′-TCCTGTCCGTCCAAGCA-3′
c-Myc-reverse
(RT)**
5′-TACGCACAAGAGTTCCGTAG-3′
GAPDH-forward
(RT)**
5′-AAGGCTGTGGGCAAGG-3′
GAPDH-reverse
(RT)**
5′-TGGAGGAGTGGGTGTCG-3′
* PC, primers used for plasmid construction.
** RT, primers used for real-time PCR detection.
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results showed that OD450nm values were higher in viral-infected
cells as compared to mock-infected cells (Fig. 1A), suggesting that
HCV enhances hepatoma cell viability. The numbers of cells were
increased during HCV infection as compared to mock infection
(Fig. 1B), indicating that HCV enhances hepatoma cell prolifera-
tion. Since the Ras/Raf/MEK/ERK pathway plays an important role
in cell proliferation, we speculated that this pathway is involved in
cell proliferation mediated by HCV. To conﬁrm this speculation, we
initially determined the effect of HCV on the phosphorylation of ERK.
The level of phosphorylated ERK (p-ERK) was higher in HCV-
infected cells as compared to mock-infected cells, whereas ERK and
GAPDHwere relatively unchanged by HCV (Fig. 1C), suggesting that
HCV stimulates the activity of ERK, leading to activating the Ras/
Raf/MEK/ERK pathway. Moreover, the effects of HCV infection on
the expression of cMyc and c-Fos, two important components down-
stream of the pathway, were investigated. The relative mRNA levels
of c-Myc (Fig. 1D), c-Fos (Fig. 1E), and HCV NS5B (Fig. 1F) were in-
creased by HCV, suggesting that HCV activates the Ras/Raf/MEK/
ERK pathway, which leads to upregulating c-Myc and c-Fos. Taken
together, we demonstrated that HCV facilitates the viability and
proliferation of human hepatoma cells through activating the Ras/
Raf/MEK/ERK pathway.
HCV represses BRD7 expression and facilitates protein degradation
Since BRD7 was reported as a potential tumor suppressor, it is
reasonable for us to postulate that BRD7may play an inhibitory role
in the regulation of HCV-associated HCC. The role of BRD7 in human
hepatoma cell proliferation mediated by HCV was then evaluated.
Initially, we investigated the effect of HCV on BRD7 expression in
HCV-infected Huh7.5.1 cells. The level of BRD7 protein was reduced
by HCV, whereas the level of HCV Core protein was signiﬁcantly in-
creased (Fig. 2A). Similarly, the relative level of HCV NS5B mRNA
was signiﬁcantly increased (Fig. 2B), whereas the relative level of
BRD7mRNAwas signiﬁcantly reduced by HCV (Fig. 2C). These results
suggested that HCV represses BRD7 expression. Since BRD7 is a tran-
scription factor, its subcellular localization was examined in Huh7.5.1
cells infected with HCV. The level of BRD7 protein was reduced by
Fig. 1. HCV facilitates the viability and proliferation of hepatoma cells through activating the Ras/Raf/MEK/ERK pathway. (A–F) Huh7.5.1 cells were infected with HCV strain
JFH-1 at MOI of 0.5 for 0, 1, 2, 3, 4, and 5 days, respectively. The viabilities of infected cells were measured by using Cell Counting Kit 8 (CCK8), and the values of OD450nm
represent cell viability. There were 6 replicate wells for each sample, and the result was expressed as the mean value ± standard deviations (SD), *p < 0.05 (A). The infected
cells were trypsinized in situ and dispersed thoroughly, and the plates were then transferred to an inverted. The cell numbers were counted under optical microscope (Olympus)
with the software ImageJ. Each sample was normalized, and the ﬁnal result was presented as the fold of control (B). Extracts of the infected cells were prepared, and phos-
phorylated ERK (p-ERK), ERK, HCV Core, and GAPDH proteins in the cell extracts were determined by Western blot analyses using corresponding antibodies (C). Total mRNAs
were extracted from infected cells. The levels of HCV NS5B mRNA along with GAPDH mRNA (D), the levels of c-Myc mRNA along with GAPDH mRNA (E), and the levels of
c-Fos mRNA and GAPDH mRNA (E) were determined by real-time PCR analyses.
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HCV in the cytoplasm (Fig. 2D, upper panel), but relatively unaf-
fected by HCV in the nucleus (Fig. 2D, lower panel), suggesting that
HCV represses BRD7 expression, but not nucleus translocation.
The mechanism by which HCV represses BRD7 expression was
then investigated in Huh7.5.1 cells transfected with pFlag-CMV-
BRD7 and infected with HCV. The level of exogenous BRD7 protein
(Flag-BRD7) was reduced during HCV infection (Fig. 2E). Because ex-
ogenous BRD7 expression is under the control of CMV promoter,
but not BRD7 promoter, our results suggested that the regulation
of exogenous BRD7 expression mediated by HCV is not at tran-
scription level, but at post-translational level. Therefore, we further
investigated the effect of HCV on BRD7 protein stability. Cells were
transfectedwith pFlag-CMV-BRD7, infected by HCV, and treatedwith
cycloheximide (CHX), an inhibitor of protein biosynthesis. The level
of BRD7 protein was gradually decreased in mock-infected cells
(Fig. 2F), but dramatically reduced in HCV-infected cells (Fig. 2G),
indicating that HCV facilitates the degradation of BRD7 protein. Taken
together, HCV represses BRD7 gene expression and facilitates BRD7
protein degradation.
Activation of Ras/Raf/MEK/ERK pathway facilitates BRD7 expression
Since HCV facilitates Ras/Raf/MEK/ERK activity and also re-
presses BRD7 expression, the correlation between Ras/Raf/MEK/
ERK activation and BRD7 expression was determined in HCV-
infected Huh7.5.1 cells. The level of BRD7 protein was reduced by
Fig. 2. HCV represses BRD7 expression and facilitates protein degradation. (A–D) Huh7.5.1 cells were infected with HCV strain JFH-1 at MOI of 0.5 for 0, 1, 2, 3, 4, and 5
days, respectively. Extracts of the infected cells were prepared, and BRD7, HCV Core, and GAPDH proteins in the cell extracts were determined by Western blot analyses
using corresponding antibodies (A). Total mRNAs were extracted from infected cells. The levels of HCV NS5B mRNA and GAPDH mRNA (B), and the levels of BRD7 mRNA
and GAPDH mRNA (C), were determined by real-time PCR analyses. Cytoplasm extracts and nucleus extracts were prepared from infected cells, the BRD7, HCV Core, and
GAPDH proteins in the cytoplasm extracts (upper panel), and the BRD7 and Lamin A proteins in the nucleus extracts (lower panel), were determined by Western blot anal-
yses using corresponding antibodies (D). (E) Huh7.5.1 cells were transfected with pFlag-CMV-BRD7 and infected with HCV strain JFH-1 at MOI of 0.5 for 0, 1, 2, 3, 4, and 5
days, respectively. Cell extracts were prepared from the treated cells, and the level of exogenous BRD7 (Flag-BRD7) and HCV Core, and GAPDH proteins in the cell extracts
were determined by Western blot analyses using corresponding antibodies. (F) Huh7.5.1 cells were transfected with pFlag-CMV-BRD7 and treated with CHX for 0, 3, 6, 9,
and 12 h, respectively. Cell extracts were prepared from treated cells, and the level of exogenous BRD7 (Flag-BRD7) and GAPDH proteins in the cell extracts were deter-
mined by Western blot analyses using corresponding antibodies. (G) Huh7.5.1 cells were transfected with pFlag-CMV-BRD7, infected with HCV strain JFH-1 at MOI of 0.5,
and then treated with CHX for 0, 3, 6, 9, and 12 h, respectively. Cell extracts were prepared from treated cells, and the level of exogenous BRD7 (Flag-BRD7), HCV Core, and
GAPDH proteins in the cell extracts were determined by Western blot analyses using corresponding antibodies.
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HCV, whereas the levels of phosphorylated ERK (p-ERK) and HCV
Core proteins were enhanced by HCV, but ERK and GAPDH pro-
teins were relatively unchanged by HCV (Fig. 3A). These results
indicated that the expression of BRD7 is negatively correlated with
the activation of Ras/Raf/MEK/ERK during HCV infection.
The role of Ras/Raf/MEK/ERK pathway in the regulation of BRD7
was then investigated. On one hand, Huh7.5.1 cells were trans-
fected with pcDNA3.1-Ras (V12), which expresses an activated Ras
(Ha-Ras), to activate the Ras/Raf/MEK/ERK pathway. BRD7 and p-ERK
proteins were upregulated by Ha-Ras, whereas EKR and GAPDH pro-
teins were not affected by Ha-Ras (Fig. 3B), demonstrating that the
activity of Ras/Raf/MEK/ERK is stimulated by Ha-Ras, which leads
to facilitating BRD7 expression. Similarly, BRD7 mRNA was en-
hanced by Ha-Ras (Fig. 3C), suggesting that activation of Ras/Raf/
MEK/ERK enhances BRD7 expression. Moreover, the mRNA levels
of c-Fos (Fig. 3D) and c-Myc (Fig. 3E), two important components
downstream of the Ras/Raf/MEK/ERK pathway, were upregulated
by Ha-Ras, conﬁrming that Ha-Ras is active and effective.
Fig. 3. Activation of Ras/Raf/MEK/ERK pathway facilitates BRD7 expression. (A) Huh7.5.1 cells were infected with HCV strain JFH-1 at MOI of 0.5 for 0, 1, 2, 3, 4, and 5 days,
respectively. Cell extracts were prepared from infected cells, and the BRD7, p-ERK, ERK, HCV Core, and GAPDH proteins in the cell extracts were determined by Western
blot analyses using corresponding antibodies. (B–E) Huh7.5.1 cells were transfected with pcDNA3.1-Ras(V12), which expresses an activated Ras (Ha-Ras), to activate the
Ras/Raf/MEK/ERK pathway. Cell extracts were prepared from the transfected cells, and the BRD7, p-ERK, ERK, and GAPDH proteins in the cell extracts were determined by
Western blot analyses using corresponding antibodies (B). Total mRNAs were extracted from infected cells. The levels of BRD7 mRNA and GAPDH mRNA (C), the levels of
c-Fos mRNA and GAPDH mRNA (D), and the levels of c-Myc mRNA and GAPDH mRNA (E) were determined by real-time PCR analyses. (F to I) Huh7.5.1 cells were treated
with U0126, a speciﬁc inhibitor of MEK1 and MEK2, to inhibit the Ras/Raf/MEK/ERK pathway. Cell extracts were prepared from the transfected cells, and the BRD7, p-ERK,
ERK, and GAPDH proteins in the cell extracts were determined by Western blot analyses using corresponding antibodies (F). Total mRNAs were extracted from infected
cells. The levels of BRD7 mRNA and GAPDH mRNA (G), the levels of c-Fos mRNA and GAPDH mRNA (H), and the levels of c-Myc mRNA and GAPDH mRNA (I), were deter-
mined by real-time PCR analyses.
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On the other hand, Huh7.5.1 cells were treated with U0126, a
speciﬁc inhibitor of MEK1 and MEK2, to inhibit the Ras/Raf/MEK/
ERK pathway. BRD7 and p-ERK proteins were downregulated by
U0126, whereas EKR and GAPDH proteins were relatively unaffect-
ed by U0126 (Fig. 3F), demonstrating that the activity of Ras/Raf/
MEK/ERK pathway is repressed by U0126, which results in
attenuating BRD7 expression. Similarly, BRD7 mRNA was reduced
by U0126 (Fig. 3G), suggesting that inhibition of Ras/Raf/MEK/ERK
leads to the repression of BRD7 expression. Moreover, c-Fos mRNA
(Fig. 3H) and c-Myc mRNA (Fig. 3I) were downregulated by U0126,
conﬁrming that repression of Ras/Raf/MEK/ERK attenuates c-Fos and
c-Myc expression. Taken together, activation of Ras/Raf/MEK/ERK
leads to upregulating BRD7 expression, whereas inhibition of the
pathway results in downregulating BRD7 production, and there-
fore, the Ras/Raf/MEK/ERK pathway plays a stimulatory role in BRD7
expression.
BRD7 attenuates hepatoma cell viability and proliferation during
HCV infection
Since HCV facilitates hepatoma cell viability and proliferation
through activating Ras/Raf/MEK/ERK, and this pathway is re-
quired for the activation of BRD7, we speculated that BRD7may play
a role in regulating hepatoma cell viability and proliferations.
Huh7.5.1 cells were transfected with pFlag-BRD7 and infected with
HCV. The results indicated that cell viabilities were higher in viral-
infected cells as compared tomock-infected cells, but HCV-mediated
activations were reduced by BRD7 (Fig. 4A), demonstrating that BRD7
attenuates hepatoma cell viability.We also showed that cell numbers
were higher during HCV infection as compared to mock infection,
but HCV-mediated upregulations were downregulated by BRD7
(Fig. 4B), demonstrating that BRD7 represses hepatoma cell
proliferation.
In addition, we revealed that the viability (Fig. 4C) and prolif-
eration (Fig. 4D) of hepatoma cells were reduced by BRD7 in dose-
dependent manners at 4 days post-transfection. Similarly, the
viability (Fig. 4E) and proliferation (Fig. 4F) of hepatoma cells were
enhanced by shBRD7 in dose-dependent fashions at 4 days post-
transfection. Moreover, cell viability (Fig. 4G) and proliferation
(Fig. 4H) were reduced by shBRD7 in time-dependent manners. Sim-
ilarly, cell viability (Fig. 4I) and proliferation (Fig. 4J) were upregulated
by shBRD7 in time-dependent fashion. These results demon-
strated that over-expression of BRD7 downregulates hepatoma cell
viability and proliferation, whereas knock-down of BRD7 upregulates
hepatoma cell of viability and proliferation.
BRD7 represses hepatoma cell viability and proliferation through
attenuating the Ras/Raf/MEK/ERK pathway
HCV facilitates cell proliferation through activating the Ras/Raf/
MEK/ERK pathway, but BRD7 attenuates cell viability and
proliferation during HCV infection. These ﬁndings intrigued us to
explore the correlation between the function of BRD7 and the ac-
tivity of Ras/Raf/MEK/ERK in Huh7.5.1 cells transfected with pFlag-
CMV-BRD7 (Fig. 5A–C) or with shBRD7 (Fig. 5D–F). Phosphorylation
of ERK (p-ERK) was attenuated by BRD7, but ERK and GAPPDHwere
relatively unaffected by BRD7 (Fig. 5A). Cyclin D1 mRNA, a cell cycle
regulator downstream of the Ras/Raf/MEK/ERK pathway, was reduced
by BRD7 (Fig. 5B), whereas BRD7 mRNA was increased, as ex-
pected (Fig. 5C). These results suggested that BRD7 attenuates the
activity of Ras/Raf/MEK/ERK. Moreover, phosphorylation of ERK (p-
ERK) was facilitated by shBRD7, whereas ERK and GAPPDHwere not
affected by shBRD7 (Fig. 5D). Cyclin D1 mRNA was upregulated by
shBRD7 (Fig. 5E), whereas BRD7 mRNA was downregulated by
shBRD7, as expected (Fig. 5F). These results indicated that the ac-
tivity of ERK is facilitated by shBRD7. Therefore, over-expression of
BRD7 downregulates the activity of Ras/Raf/MEK/ERK, whereas
knock-down of BRD7 upregulates the activity of this pathway.
Moreover, Huh7.5.1 cells were co-transfected with pcDNA3.1-Ras
(V12) and pFlag-BRD7. The results showed that cell viability (Fig. 5G)
and proliferation (Fig. 5H) were upregulated by Ha-Ras, but such
activations were attenuated by BRD7. Therefore, activation of Ras/
Raf/MEK/ERK leads to the upregulation of cell viability and
proliferation, and BRD7 downregulates cell viability and prolifer-
ation. Finally, Huh7.5.1 cells were treatedwith U0126 and transfected
with pFlag-CMV-BRD7. The results revealed that cell viability (Fig. 5I)
and proliferation (Fig. 5J) were downregulated by U0126, and further
reduced by BRD7. Therefore, inhibition of Ras/Raf/MEK/ERK results
in the downregulation of cell viability and proliferation, and over-
expression of BRD7 leads to the reduction of cell viability and
proliferation. Taken together, we demonstrated that BRD7 re-
presses the viability and proliferation of hepatoma cells through
attenuating the activity of Ras/Raf/MEK/ERK pathway.
Discussion
Although HCV infection has a profound impact on cell prolifer-
ation, the exact mechanism underlying such regulation is very
complicated and remains largely elusive. We previously reported
that during HCV infection, the Ras/Raf/MEK/ERK pathway is acti-
vated, which in turn attenuates the IFN/JAK/STAT signaling, resulting
in the stimulation of HCV replication [30]. Since the Ras/Raf/MEK/
ERK pathway plays an important role in the regulation of cell
proliferation and differentiation, in this study, we further revealed
the mechanism by which HCV regulates hepatoma cell prolifera-
tion and HCC development. Initially, the effect of HCV on cell
proliferation was evaluated. After conﬁrming that HCV enhances the
proliferation of human hepatoma cells, we speculated that the Ras/
Raf/MEK/ERK pathway may be involved in HCV-mediated cell
proliferation. The results indeed revealed that HCV activates Ras/
Raf/MEK/ERK pathway by stimulating ERK activity and activating
c-Myc and c-Fos expression, and further demonstrated that HCV fa-
cilitates of human hepatoma cell proliferation through activating
Ras/Raf/MEK/ERK signaling.
In the process of evaluating the mechanism underlying such reg-
ulation, we revealed that HCV represses BRD7 expression and
facilitates protein degradation. Because HCV facilitates the Ras/Raf/
MEK/ERK signaling and also attenuates BRD7 expression, the
correlation between Ras/Raf/MEK/ERK activation and BRD7 expres-
sionwas determined. Activation of Ras/Raf/MEK/ERK by Ha-Ras leads
to the upregulation of BRD7, whereas inhibition of Ras/Raf/MEK/
ERK by U0126 results in the downregulation of BRD7, demonstrating
the Ras/Raf/MEK/ERK pathway plays a stimulatory role in BRD7
expression.
Since HCV facilitates hepatoma cell proliferation and also re-
presses BRD7 expression, it is reasonable for us to postulate that
BRD7 may play a role in the regulation of hepatoma cell prolifer-
ation mediated by HCV. To conform this speculation, we initially
demonstrated that over-expression of BRD7 leads to the
downregulation of cell proliferation, whereas knock-down of BRD7
results in the upregulation of cell proliferation. Therefore, BRD7 acts
as a suppressor in the regulating hepatoma cell proliferation during
HCV infection. These results suggested that HCV may induce HCC
through repressing the tumor suppressor, BRD7. BRD7 is involved
in the regulation of cell cycle, and has a close relationship with the
well-known tumor suppressor p53 [26,35–37]. Although previous
studies reported that BRD7 has tumor-suppressive roles in several
cancers [21–24,38], some studies demonstrated that BRD7 has no
correlation with many tumors [38–41]. Therefore, we at the ﬁrst
time revealed that BRD7 acts as a tumor suppressor in the regula-
tion of hepatoma cell proliferation and perhaps HCC development.
Furthermore, the effect of BRD7 on apoptosis was investigated, since
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it is a common feature of tumor suppressors to stimulate apopto-
sis. The results showed that the levels of apoptosis were increased
in the presence of BRD7 (Fig. S1), indicating that BRD7 has effects
on pro-apoptosis. Recent reports demonstrated that HCV could an-
tagonize cell apoptosis [42,43]. Here, we offer a new approach for
apoptosis antagonizing of HCV through repressing the BRD7
expression.
Because HCV facilitates hepatoma cell proliferation through ac-
tivating Ras/Raf/MEK/ERK and this pathway can activate the
expression of BRD7, which in turn attenuates cell proliferation, these
Fig. 4. BRD7 attenuates hepatoma cell viability and proliferation during HCV infection. (A and B) Huh7.5.1 cells were transfected with/without pFlag-CMV-BRD7 and in-
fected with/without HCV strain JFH-1. (C–F) Huh7.5.1 cells were transfected with pFlag-BRD7 (C and D) or shBRD7 (E and F) at concentration of 0, 0.5, 1, and 2 μg, and then
infected with HCV strain JFH-1 for 0 and 4 days. (G–J) Huh7.5.1 cells were transfected with pFlag-BRD7 (G and H) or shBRD7 (I and J) for 0, 1, 2, 3, 4, 5, and 6 days. The
viabilities of treated cells were measured with Cell Counting Kit 8 (CCK8). The values of OD450nm represent cell viability. There are 6 replicate wells for each sample, and
the result was expressed as the mean value ± standard deviations (SD). *p < 0.05 (A, C, E, G, and I). The treated cells were trypsinized in situ and dispersed thoroughly, and
the plate was then transferred to an inverted optical microscope (Olympus). The cell numbers were counted with the software ImageJ. Each sample was normalized, and
the ﬁnal result was presented as the fold of control (B, D, F, H, and J).
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results intrigued us to explore the correlation between the activi-
ty of Ras/Raf/MEK/ERK and the function of BRD7. Interestingly, over-
expression of BRD7 downregulates Ras/Raf/MEK/ERK signaling,
whereas knock-down of BRD7 upregulates this pathway, and dem-
onstrated that BRD7 represses hepatoma cell proliferation through
attenuating Ras/Raf/MEK/ERK. The Ras/Raf/MEK/ERK signaling is an
important pathway with multiple functions, including regulation
of proliferation, apoptosis, and cell cycle. Therefore, inhibition of
Ras/Raf/MEK/ERK signaling mediated by BRD7 may provide an im-
portant mechanism underlying the regulation of caner development,
Fig. 5. BRD7 represses hepatoma cell viability and proliferation through attenuating the Ras/Raf/MEK/ERK pathway. (A–F) Huh7.5.1 cells were transfected with pFlag-CMV-
BRD7 (A–C) or shBRD7 at concentration of 0, 0.5, 1, and 2 μg for 48 h (D–F). Cell extracts were prepared from the treated cells, and p-ERK, ERK, BRD7, and GAPDH in the cell
extracts were determined by Western blot analyses using corresponding antibodies (A and D). Total mRNAs were extracted from the transfected cells. The levels of cyclin
D1 mRNA and GAPDH mRNA (B and E), and the levels of BRD7 mRNA and GAPDH mRNA (C and F), were determined by real-time PCR analyses. (G–J) Huh7.5.1 cells were
co-transfected with pcDNA3.1-Ras(V12) and pFlag-CMV-BRD7 for 0, 1, 2, 3, 4, and 5 days (G and H) or treated with U0126 for 0, 1, 2, 3, 4, and 5 days (I and J). The viabilities
of infected cells were measured with Cell Counting Kit 8 (CCK8), and the values of OD450nm represent cell viability. There are 6 replicate wells for each sample, and the
result was expressed as the mean value ± standard deviations (SD). *p < 0.05 (G and I). The infected cells were trypsinized in situ and dispersed thoroughly, and the plates
were then transferred to an inverted optical microscope (Olympus). The cell numbers were counted with the software ImageJ. Each sample was normalized, and the ﬁnal
result was presented as the fold of control (H and J).
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although detailed mechanism underlying such regulation needs to
be elucidated.
In conclusion, we proposed a novel and important mechanism
underlying the regulation of HCC development mediated by HCV
infection (Fig. 6). On one hand, hepatoma cell proliferation is fa-
cilitated by a positive feedback regulatory cycle during HCV infection.
The virus promotes hepatoma cell proliferation by activating the Ras/
Raf/MEK/ERK pathway, which in turn facilitates HCV replication by
repressing the IFN/JAK/STAT signaling [30], leading to further fa-
cilitation of hepatoma cell proliferation. On the other hand, hepatoma
cell proliferation is attenuated by a negative feedback regulatory
mechanism. After activation, the Ras/Raf/MEK/ERK pathway stimu-
lates the tumor suppressor BRD7, which in turn represses the Ras/
Raf/MEK/ERK signaling, leading to the attenuation of hepatoma cell
proliferation. However, HCV persistent infection attenuates BRD7
gene expression and facilitates the protein degradation to release
the Ras/Raf/MEK/ERK signaling, which results in the facilitation of
hepatoma cell proliferation. Therefore, the balance between BRD7
function and Ras/Raf/MEK/ERK activity is important for determin-
ing the outcomes of HCV infection and HCC development.
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